Clinical trial
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute…
NCT00003407 · Rush University Medical Center, Other · Withdrawn
Key facts
| NCT number | NCT00003407 |
|---|---|
| Title | Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML |
| Official title | Treatment of Poor Prognosis Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone and Ethyol AML/CML 2000-06. |
| Lead sponsor | Rush University Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia |
| Intervention type | Drug |
| Interventions | amifostine trihydrate, cytarabine, mitoxantrone hydrochloride |
| Enrollment | 0 |
| Start date | Feb 13, 2001 |
| Primary completion | Apr 7, 2004 |
| Completion | Apr 7, 2004 |
| First posted | Apr 27, 2004 |
| Last update posted | Feb 2, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: